NCT05677932Completed
Bright Light Therapy for Post-COVID-19 Fatigue
Source: ClinicalTrials.gov · Last updated 20 Mar 2026
Brief summary (registry, in English)
This is a randomized placebo-controlled trial to examine the efficacy of two-week bright light therapy for patients with post-COVID-19 fatigue.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 12 (actual)
- First submitted
- 6 Jan 2023
- Start date
- 15 Feb 2023
- Primary completion date
- 28 Feb 2024
- Lead sponsor
- Chinese University of Hong Kong
- Diseases
- Long COVID and ME/CFS
- NCT number
- NCT05677932
What you commit to
- Study type: Interventional
- Participants enrolled: 12
- From 15 Feb 2023 to the primary completion date, 28 Feb 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Currently receiving any structured psychotherapy
Other illness
- A current or past history of bipolar disorder, schizophrenia, neurodevelopmental disorder, organic mental disorder; intellectual disabilities or substance use disorder.
- Presence of contraindications to bright light therapy: for example, history of light induced migraine/ epilepsy; current use of photosensitizing medications; presence of eye disease: e.g. retinal blindness, severe cataract, glaucoma.
- Significant medical condition/ hearing impairment/ speech deficit leading to incapability of completing clinical interview.
- Self-reported untreated sleep disorders (e.g. severe insomnia, obstructive sleep apnea, restless leg syndrome), psychiatric illness (e.g. depression), or medical conditions associated with fatigue (e.g. anemia, heart failure, autoimmune disorders)
Other
- Regular shift-workers
- Trans-meridian flight in the past 3 months and during the study
- Enrolment in another clinical trial of an investigational medicinal product or device.
Who the study is looking for
- Age 18 or above
- Capable to give informed consent
- COVID-19 infection confirmed by PCR test or a Rapid Antigen Test (RAT) with onset of at least three months
- Reports new onset or exacerbation of fatigue after onset of COVID-19 and lasted for over two months
- Scoring 7 or above for the item "worst level of fatigue during the last 24 hours" in the Brief Fatigue Inventory
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The Chinese University of Hong Kong Coordinator of this site? Confirm its status | Hong Kong | Hong Kong | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.